A Study to Assess Potential Interaction Between ASP8062 and Alcohol in Healthy Adult Subjects
- Conditions
- Healthy Volunteers
- Interventions
- First Posted Date
- 2019-07-01
- Last Posted Date
- 2024-11-05
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT04003402
- Locations
- 🇺🇸
Parexel International - EPCU Baltimore, Baltimore, Maryland, United States
A Study to Find Out How Safe Long-term Treatment With Fezolinetant is in Women With Hot Flashes Going Through Menopause
- First Posted Date
- 2019-07-01
- Last Posted Date
- 2024-11-05
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 1831
- Registration Number
- NCT04003389
- Locations
- 🇺🇸
SEC Clinical Research, Andalusia, Alabama, United States
🇺🇸Alabama Clinical Therapeutics, LLC, Birmingham, Alabama, United States
🇺🇸Achieve Clinical Research, LLC, Ensley, Alabama, United States
A Study to Assess the Relative Bioavailability of Gilteritinib Following a Single Dose of Gilteritinib Mini-tablet Oral Suspension and Gilteritinib Mini-tablets Compared to a Single Dose of Gilteritinib Tablet in Healthy Subjects
- Conditions
- Healthy Volunteer
- Interventions
- First Posted Date
- 2019-05-28
- Last Posted Date
- 2024-10-16
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 48
- Registration Number
- NCT03964038
- Locations
- 🇺🇸
EPCU - Parexel, Baltimore, Maryland, United States
A Study to Assess the Relative Bioavailability of Roxadustat Following a Single Dose of Pediatric Azo Dye-free Tablet Formulation and Pediatric Azo Dye-free Mini-tablet Formulation Compared to a Single Dose of Azo Dye-containing Tablet Formulation in Healthy Adult Subjects
- First Posted Date
- 2019-05-23
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT03960489
- Locations
- 🇩🇪
Site DE49001, Berlin, Germany
A Study of an Intratumoral Oncolytic Virus in Patients With Advanced Metastatic Solid Tumors
- Conditions
- Metastatic CancerSolid TumorsAdvanced Cancer
- Interventions
- Combination Product: Pembrolizumab
- First Posted Date
- 2019-05-17
- Last Posted Date
- 2025-04-22
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 72
- Registration Number
- NCT03954067
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸University of Arizona - Arizona Cancer Center, Tucson, Arizona, United States
🇺🇸The Angeles Clinic and Research Institute, Los Angeles, California, United States
A Study to Evaluate Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Participants
- Conditions
- Invasive MucormycosisInvasive Aspergillosis
- Interventions
- First Posted Date
- 2019-01-25
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 31
- Registration Number
- NCT03816176
- Locations
- 🇺🇸
Children's Hospital, Los Angeles, Los Angeles, California, United States
🇺🇸University of California - Los Angeles, Los Angeles, California, United States
🇺🇸Children's Hospital of Orange County, Orange, California, United States
A Study of Zolbetuximab (IMAB362) in Adults With Pancreatic Cancer
- Conditions
- Pancreatic CancerMetastatic Pancreatic CancerMetastatic Pancreatic Adenocarcinoma
- Interventions
- First Posted Date
- 2019-01-25
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 393
- Registration Number
- NCT03816163
- Locations
- 🇺🇸
St. Joseph Heritage Medical Group, Fullerton, California, United States
🇺🇸TOI Clinical research, Whittier, California, United States
🇺🇸Midstate Medical Center, Meriden, Connecticut, United States
A Study of ASP1951 in Subjects With Advanced Solid Tumors
- First Posted Date
- 2019-01-10
- Last Posted Date
- 2024-11-01
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 119
- Registration Number
- NCT03799003
- Locations
- 🇺🇸
Arizona Clinical Research Cent, Tucson, Arizona, United States
🇺🇸University of California, Sacramento, California, United States
🇺🇸University of Florida, Davis C, Gainesville, Florida, United States
A Study to Assess the Safety and Efficacy of ASP1650, a Monoclonal Antibody Targeting Claudin 6 (CLDN6), in Male Subjects With Incurable Platinum Refractory Germ Cell Tumors
- Conditions
- Incurable Platinum Refractory Germ Cell TumorsTumors
- Interventions
- First Posted Date
- 2018-11-30
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 19
- Registration Number
- NCT03760081
- Locations
- 🇺🇸
Indiana University Simon Cancer Center, Indianapolis, Indiana, United States
🇺🇸Memorial Sloan-Kettering Cancer Center, New York, New York, United States
🇺🇸Abramson Cancer Center University of Pennsylvania, Philadelphia, Pennsylvania, United States
A Study to Evaluate Safety, Tolerability and Immune Response in Adolescents Allergic to Peanut After Receiving Intradermal Administration of ASP0892 (ARA-LAMP-vax), a Single Multivalent Peanut (Ara h1, h2, h3) Lysosomal Associated Membrane Protein DNA Plasmid Vaccine
- First Posted Date
- 2018-11-28
- Last Posted Date
- 2024-10-23
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT03755713
- Locations
- 🇺🇸
Arkansas Children's Hospital Research Institute, Little Rock, Arkansas, United States
🇺🇸Sean N Parker Center for Allergy & Asthma Research, LPCH El Camino Hospital, Mountain View, California, United States
🇺🇸The University of Chicago Medicine, Chicago, Illinois, United States